GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1alpha signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure. Form: Beige Solid Melting Point: 195-197C Solubility: Methanol
Molekulargewicht:
348.33
Formulierung:
Beige Solid
CAS Nummer:
[931399-19-8]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten